Degron Therapeutics Participated at UBS Virtual Targeted Protein Degradation Day

Degron Therapeutics Inc. CEO & Co-founder, Lily Zou, PhD, participated in a fireside chat at the Virtual Targeted Protein Degradation (TPD) Day hosted by the Swiss investment bank UBS.

By Degron, July 15, 2024 

Degron Therapeutics Announces Multi-Target Collaboration and Exclusive License Agreement with Takeda to Discover Molecular Glue Degraders

Collaboration will leverage Degron's GlueXplorer® platform to discover novel molecular glue degraders for multiple targets in oncology, neuroscience, and inflammation. Degron will receive upfront payment and potential milestone payments of up to $1.2 billion. Takeda to make equity investment in the company

By Degron, May 23, 2024 

Degron Therapeutics won the 2023 BRACE Award Venture Competition along with the investment from Asian Fund for Cancer Research (AFCR)

Degron Therapeutics was selected as the winner of the 2023 BRACE Award Venture Competition after thr

By Degron,  December 18, 2023 

Degron Therapeutics Wins the Second Prize in 2023 Women’s Venture Competition, the First Asian Company to Win in this Global Competition

Degron Therapeutics and its Co-founder and CEO, Lily Zou, Ph.D., MBA won the Second Prize in 2023 Wo

By Degron,  October 18, 2023 

Dr. Xiaobing Qian joins Degron Therapeutics as Chief Development Officer

Degron Therapeutics Inc. announced today that Xiaobing Qian, M.D., Ph.D., recently joined the company as Chief Development Officer and a member of the executive management team. Dr. Qian will lead the company’s translational medicine, preclinical development, and early clinical development.

By Degron,  Feb. 7, 2023 

Degron Therapeutics Co-Founder is invited to speak at the TPD meeting in San Diego

Dr. Yong Cang, CSO and Co-Founder of Degron Therapeutics, who has dedicated his research to the TPD

By Degron,  Dec. 6, 2022 

Degron Therapeutics Co-Founder Provides New Strategy for Molecular Glue in Tumor Immunotherapy

Research published in Cell Chemical Biology showed lenalidomide can enhance cancer-treating ability

By Degron,  June 28, 2022,  

Degron Therapeutics Raises $22M Series A Financing to Accelerate Growth and Expand Molecular-Glue-Based Targeted Protein Degradation Drug Discovery Platform

SAN DIEGO, Calif., and SHANGHAI, China, June 9, 2022 - Degron Therapeutics (“Degron”), a biotechnolo

By Degron,  June 09,2022 

Degron Therapeutics Had an Exclusive Interview with CCTV2 "Economy 30 Minutes" Program

At 8:00 p.m. on March 11, 2022, the prime-time program “Economy 30 Minutes” on CCTV2 broadcast a spe

By Degron,  March 11, 2022 

The Theme Activities of "Degron Date" Concluded Successfully

With lush greens and pleasant weather, Shanghai headed into the best March spring. Degron empoyees g

By Degron, March 10, 2022 

Molecular Glue Degraders，a New Dawn Since PROTACs

Yong Cang, professor of ShanghaiTech University and co-founder of Degron Therapeutics

By Yong Cang,  August 18, 2020,